Skip to main content
SpringerLink
Log in

Immunobiology of the Pituitary Adenylate Cyclase-Activating Peptide

  • Chapter
  • First Online:
Pituitary Adenylate Cyclase Activating Polypeptide — PACAP

Part of the book series: Current Topics in Neurotoxicity ((Current Topics Neurotoxicity,volume 11))

  • 534 Accesses

Abstract

The immune system is faced with the daunting job of defending the organism against invading pathogens, while at the same time maintaining tolerance to the body’s own tissues, thereby preserving its integrity. Loss of immune tolerance compromises immune homeostasis and results in the onset of autoimmune disorders. Identification of the endogenous factors that control immune tolerance and inflammation is a key goal in the field of immunology. Evidences from the last two decades indicate that the neuropeptide pituitary adenylate cyclase-activating peptide (PACAP) is one of these endogenous factors. PACAP is produced by immune cells, and through its binding to specific receptors, it exerts potent anti-inflammatory actions and participates in the maintenance of immune tolerance at multiple levels, especially in immunological disorders. Therefore, PACAP is a key element in the bidirectional communication that exists between the neuroendocrine and immune systems in order to maintain body’s homeostasis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Goodnow CC. Multistep pathogenesis of autoimmune diseases. Cell. 2007;130:25–35.

    Article  CAS  PubMed  Google Scholar 

  2. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10:490–500.

    Article  CAS  PubMed  Google Scholar 

  3. Sternberg EM. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol. 2006;6:318–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Gonzalez-Rey E, Chorny A, Delgado M. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat Rev Immunol. 2007;7:52–63.

    Article  CAS  PubMed  Google Scholar 

  5. Gaytan F, Martinez-Fuente AJ, Gracia-Navarro F, Vaudry H, Aguilar E. Pituitary adenylate cyclase-activating peptide (PACAP) immunolocalization in lymphoid tissues of the rat. Cell Tissue Res. 1994;276:223–7.

    Article  CAS  PubMed  Google Scholar 

  6. Abad C, Martinez C, Leceta J, Juarranz MG, Delgado M, Gomariz RP. Pituitary adenylate-cyclase-activating polypeptide expression in the immune system. Neuroimmunomodulation. 2002;10:177–86.

    Article  CAS  PubMed  Google Scholar 

  7. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev. 2004;56:249–90.

    Article  CAS  PubMed  Google Scholar 

  8. Delgado M, Ganea D. Cutting edge: is vasoactive intestinal peptide a type 2 cytokine? J Immunol. 2001;166:2907–12.

    Article  CAS  PubMed  Google Scholar 

  9. Harmar A, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna J, et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev. 1998;50:265–70.

    CAS  PubMed  Google Scholar 

  10. Pozo D, Delgado M, Martinez C, Gomariz RP, Guerrero JM, Calvo JR. Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal macrophages. Biochim Biophys Acta. 1997;1359:250–62.

    Article  CAS  PubMed  Google Scholar 

  11. Guerrero J, Prieto J, Elorza F, Ramirez R, Goberna R. Interaction of vasoactive intestinal peptide with human blood mononuclear cells. Mol Cell Endocrinol. 1981;21:151–60.

    Article  CAS  PubMed  Google Scholar 

  12. Delgado M, Gomariz RP, Martinez C, Abad C, Leceta J. Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock. Eur J Immunol. 2000;30:3236–46.

    Article  CAS  PubMed  Google Scholar 

  13. Gonzalez-Rey E, Delgado M. Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders? Trends Pharmacol Sci. 2007;28:482–91.

    Article  CAS  PubMed  Google Scholar 

  14. Goetzl EJ, Voice JK, Shen S, Dorsam G, Kong Y, West KM, et al. Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide. Proc Natl Acad Sci U S A. 2001;98:13854–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Lauenstein HD, Quarcoo D, Plappert L, Schleh C, Nassimi M, Pilzner C, et al. Pituitary adenylate cyclase-activating peptide receptor 1 mediates anti-inflammatory effects in allergic airway inflammation in mice. Clin Exp Allergy. 2011;41:592–601.

    Article  CAS  PubMed  Google Scholar 

  16. Martinez C, Abad C, Delgado M, Arranz A, Juarranz MG, Rodriguez-Henche N, et al. Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc Natl Acad Sci U S A. 2002;99:1053–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Martínez C, Juarranz Y, Abad C, Arranz A, Miguel BG, Rosignoli F, et al. Analysis of the role of the PAC1 receptor in neutrophil recruitment, acute-phase response, and nitric oxide production in septic shock. J Leukoc Biol. 2005;77:729–38.

    Article  PubMed  Google Scholar 

  18. Samarasinghe AE, Hoselton SA, Schuh JM. The absence of VPAC2 leads to aberrant antibody production in Aspergillus fumigatus sensitized and challenged mice. Peptides. 2011;32:131–7.

    Article  CAS  PubMed  Google Scholar 

  19. Tan YV, Abad C, Wang Y, Lopez R, Waschek JA. VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses. Brain Behav Immun. 2015;44:167–75.

    Article  CAS  PubMed  Google Scholar 

  20. Delgado M, Robledo G, Rueda B, Varela N, O'Valle F, Hernandez-Cortes P, et al. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells. Arthritis Rheum. 2008;58:1010–9.

    Article  CAS  PubMed  Google Scholar 

  21. Juarranz Y, Gutierrez-Canas I, Santiago B, Carrion M, Pablos JL, Gomariz RP. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum. 2008;58:1086–95.

    Article  CAS  PubMed  Google Scholar 

  22. Paladini F, Cocco E, Cauli A, Cascino I, Vacca A, Belfiore F, et al. A functional polymorphism of the vasoactive intestinal peptide receptor 1 gene correlates with the presence of HLA-B*2705 in Sardinia. Genes Immun. 2008;9:659–67.

    Article  CAS  PubMed  Google Scholar 

  23. Paladini F, Belfiore F, Cocco E, Carcassi C, Cauli A, Vacca A, et al. HLA-E gene polymorphism associates with ankylosing spondylitis in Sardinia. Arthritis Res Ther. 2009;11:R171.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Cocco E, Paladini F, Macino G, Fulci V, Fiorillo MT, Sorrentino R. The expression of vasoactive intestinal peptide receptor 1 is negatively modulated by microRNA 525-5p. PLoS One. 2010;5:e12067.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Paladini F, Porciello N, Camilli G, Tuncer S, Cocco E, Fiorillo MT, et al. Single nucleotide polymorphisms in the 3′UTR of VPAC-1 cooperate in modulating gene expression and impact differently on the interaction with miR525-5p. PLoS One. 2014;9:e112646.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Sun W, Hong J, Zang YC, Liu X, Zhang JZ. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. Int Immunol. 2006;18:1691–700.

    Article  CAS  PubMed  Google Scholar 

  27. Delgado M, Garrido E, de la Fuente M, Gomariz RP. Pituitary adenylate cyclase-activating polypeptide (PACAP-38) stimulates rat peritoneal macrophage functions. Peptides. 1996;17:1097–105.

    Article  CAS  PubMed  Google Scholar 

  28. Garrido E, Delgado M, Martínez C, Gomariz RP, De la Fuente M. Pituitary adenylate cyclase-activating polypeptide (PACAP38) modulates lymphocyte and macrophage functions: stimulation of adherence and opposite effect on mobility. Neuropeptides. 1996;30:583–95.

    Article  CAS  PubMed  Google Scholar 

  29. Martínez C, Delgado M, Pozo D, Leceta J, Calvo JR, Ganea D, et al. VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies. J Neuroimmunol. 1998;85:155–67.

    Article  PubMed  Google Scholar 

  30. Delgado M, Anderson P, Garcia-Salcedo JA, Caro M, Gonzalez-Rey E. Neuropeptides kill African trypanosomes by targeting intracellular compartments and inducing autophagic-like cell death. Cell Death Differ. 2009;16:406–16.

    Article  CAS  PubMed  Google Scholar 

  31. Delgado M, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation. J Biol Chem. 1999;274(45):31930–40.

    Article  CAS  PubMed  Google Scholar 

  32. Delgado M, Ganea D. Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J. 2003;7:1922–4.

    Google Scholar 

  33. Delgado M, Munoz-Elias EJ, Kan Y, Gozes I, Fridkin M, Brenneman DE, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun. J Biol Chem. 1998;273:31427–36.

    Article  CAS  PubMed  Google Scholar 

  34. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol. 1999;162:1707–16.

    CAS  PubMed  Google Scholar 

  35. Delgado M, Pozo D, Martinez C, Leceta J, Calvo JR, Ganea D, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. J Immunol. 1999;162:2358–67.

    CAS  PubMed  Google Scholar 

  36. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J Neuroimmunol. 1999;96:167–81.

    Article  CAS  PubMed  Google Scholar 

  37. Delgado M, Leceta J, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. J Leukoc Biol. 2003;73:155–64.

    Article  CAS  PubMed  Google Scholar 

  38. Kim WK, Kan Y, Ganea D, Hart RP, Gozes I, Jonakait GM. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway. J Neurosci. 2000;20:3622–30.

    CAS  PubMed  Google Scholar 

  39. Martínez C, Delgado M, Pozo D, Leceta J, Calvo JR, Ganea D, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukoc Biol. 1998;63:591–601.

    PubMed  Google Scholar 

  40. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation. J Immunol. 1999;162:4685–96.

    CAS  PubMed  Google Scholar 

  41. Gonzalez-Rey E, Delgado M. Vasoactive intestinal peptide inhibits cyclooxygenase-2 expression in activated macrophages, microglia, and dendritic cells. Brain Behav Immun. 2008;22:35–41.

    Article  CAS  PubMed  Google Scholar 

  42. Delgado M, Ganea D. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J Immunol. 2001;167:966–75.

    Article  CAS  PubMed  Google Scholar 

  43. Delgado M, Ganea D. Vasoactive intestinal peptide inhibits IL-8 production in human monocytes. Biochem Biophys Res Commun. 2003;301:825–32.

    Article  CAS  PubMed  Google Scholar 

  44. Delgado M, Jonakait GM, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Glia. 2002;39:148–61.

    Article  PubMed  Google Scholar 

  45. Tang Y, Lv B, Wang H, Xiao X, Zuo X. PACAP inhibit the release and cytokine activity of HMGB1 and improve the survival during lethal endotoxemia. Int Immunopharmacol. 2008;8:1646–51.

    Article  CAS  PubMed  Google Scholar 

  46. Delgado M, Varela N, Gonzalez-Rey E. Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels. Glia. 2008;56:1091–103.

    Article  PubMed  Google Scholar 

  47. Mao SS, Hua R, Zhao XP, Qin X, Sun ZQ, Zhang Y, et al. Exogenous administration of PACAP alleviates traumatic brain injury in rats through a mechanism involving the TLR4/MyD88/NF-kB pathway. J Neurotrauma. 2012;29:1941–59.

    Article  PubMed  Google Scholar 

  48. Reglodi D, Renaud J, Tamas A, Tizabi Y, Socías B, Del-Bel E, et al. Novel tactics for neuroprotection in Parkinson’s disease: role of antibiotics, polyphenols and neuropeptides. Prog Neurobiol. 2015; pii: S0301-0082(15)00128-8.

    Google Scholar 

  49. Azuma YT, Hagi K, Shintani N, Kuwamura M, Nakajima H, Hashimoto H, et al. PACAP provides colonic protection against dextran sodium sulphate induced colitis. J Cell Physiol. 2008;216:111–9.

    Article  CAS  PubMed  Google Scholar 

  50. Botz B, Bölcskei K, Kereskai L, Kovács M, Németh T, Szigeti K, et al. Differential regulatory role of pituitary adenylate cyclase-activating polypeptide in the serum-transfer arthritis model. Arthritis Rheumatol. 2014;66:2739–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Nemetz N, Abad C, Lawson G, Nobuta H, Chhith S, Duong L, et al. Induction of colitis and rapid development of colorectal tumors in mice deficient in the neuropeptide PACAP. Int J Cancer. 2008;122:1803–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Delgado M. Inhibition of interferon (IFN) gamma-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide: inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression. J Biol Chem. 2003;278:27620–9.

    Article  CAS  PubMed  Google Scholar 

  53. Delgado M, Gonzalez-Rey E, Ganea D. VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. FASEB J. 2004;18:1453–5.

    CAS  PubMed  Google Scholar 

  54. Delgado M, Reduta A, Sharma V, Ganea D. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells. J Leukoc Biol. 2004;75:1122–30.

    Article  CAS  PubMed  Google Scholar 

  55. Delgado M. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia. Biochem Biophys Res Commun. 2002;293:771–6.

    Article  CAS  PubMed  Google Scholar 

  56. Delgado M, Ganea D. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J Immunol. 2000;165:3051–7.

    Article  CAS  PubMed  Google Scholar 

  57. Delgado M, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages. J Neuroimmunol. 2000;110:97–105.

    Article  CAS  PubMed  Google Scholar 

  58. Delgado M, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1. J Biol Chem. 2001;276:369–80.

    Article  CAS  PubMed  Google Scholar 

  59. Chorny A, Gonzalez-Rey E, Varela N, Robledo G, Delgado M. Signaling mechanisms of vasoactive intestinal peptide in inflammatory conditions. Regul Pept. 2006;137:67–74.

    Article  CAS  PubMed  Google Scholar 

  60. Delgado M, Leceta J, Abad C, Martinez C, Ganea D, Gomariz RP. Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide. J Neuroimmunol. 1999;99:61–71.

    Article  CAS  PubMed  Google Scholar 

  61. Delgado M, Sun W, Leceta J, Ganea D. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B.71 and B.72 expression. J Immunol. 1999;163:4213–23.

    CAS  PubMed  Google Scholar 

  62. Ganea D, Rodriguez R, Delgado M. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity. Cell Mol Biol. 2003;49:127–42.

    CAS  PubMed  Google Scholar 

  63. Martinez C, Delgado M, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes. J Immunol. 1996;156:4128–36.

    CAS  PubMed  Google Scholar 

  64. Wang HY, Jiang XM, Ganea D. The neuropeptides VIP and PACAP inhibit IL-2 transcription by decreasing c-Jun and increasing JunB expression in T cells. J Neuroimmunol. 2000;104:68–78.

    Article  CAS  PubMed  Google Scholar 

  65. Delgado M, Leceta J, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J. 2002;16:1844–6.

    CAS  PubMed  Google Scholar 

  66. Tan YV, Abad C, Lopez R, Dong H, Liu S, Lee A, et al. Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2009;106:2012–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Voice JK, Grinninger C, Kong Y, Bangale Y, Paul S, Goetzl EJ. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J Immunol. 2003;170:308–14.

    Article  CAS  PubMed  Google Scholar 

  68. Voice J, Donnelly S, Dorsam G, Dolganov G, Paul S, Goetzl EJ. c-Maf and JunB mediation of Th2 differentiation induced by the type 2G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide. J Immunol. 2004;172:7289–96.

    Article  CAS  PubMed  Google Scholar 

  69. Delgado M, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression. J Immunol. 2001;165:114–23.

    Article  Google Scholar 

  70. Delgado M, Ganea D. VIP and PACAP inhibit Fas ligand-mediated bystander lysis by CD4(+) T cells. J Neuroimmunol. 2001;112:78–88.

    Article  CAS  PubMed  Google Scholar 

  71. Delgado M, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3. J Immunol. 2001;166:1028–40.

    Article  CAS  PubMed  Google Scholar 

  72. Sharma V, Delgado M, Ganea D. Granzyme B, a new player in activation-induced cell death, is down-regulated by vasoactive intestinal peptide in Th2 but not Th1 effectors. J Immunol. 2006;176:97–110.

    Article  CAS  PubMed  Google Scholar 

  73. Jiang X, Jing H, Ganea D. VIP and PACAP down-regulate CXCL10 (IP-10) and up-regulate CCL22 (MDC) in spleen cells. J Neuroimmunol. 2002;133:81–94.

    Article  CAS  PubMed  Google Scholar 

  74. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123–32.

    Article  CAS  PubMed  Google Scholar 

  75. Delgado M, Chorny A, Gonzalez-Rey E, Ganea D. Vasoactive intestinal peptide generates CD4 + CD25+ regulatory T cells in vivo. J Leukoc Biol. 2005;78:1327–38.

    Article  CAS  PubMed  Google Scholar 

  76. Heimesaat MM, Dunay IR, Schulze S, Fischer A, Grundmann U, Alutis M, et al. Pituitary adenylate cyclase-activating polypeptide ameliorates experimental acute ileitis and extra-intestinal sequelae. PLoS One. 2014;9:e108389.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Tan YV, Abad C, Wang Y, Lopez R, Waschek JA. Pituitary adenylate cyclase activating peptide deficient mice exhibit impaired thymic and extrathymic regulatory T cell proliferation during EAE. PLoS One. 2013;8:e61200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Pozo D, Anderson P, Gonzalez-Rey E. Induction of alloantigen-specific human T regulatory cells by vasoactive intestinal peptide. J Immunol. 2009;183:4346–59.

    Article  CAS  PubMed  Google Scholar 

  79. Prasse A, Zissel G, Lutzen N, Schupp J, Schmiedlin R, Gonzalez-Rey E, et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med. 2010;182:540–8.

    Article  CAS  PubMed  Google Scholar 

  80. Anderson P, Gonzalez-Rey E. Vasoactive intestinal peptide induces cell cycle arrest and regulatory functions in human T cells at multiple levels. Mol Cell Biol. 2010;30:2537–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol. 2010;108:111–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Pozo D, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc Natl Acad Sci U S A. 2005;102:13562–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Delgado M, Gonzalez-Rey E, Ganea D. The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol. 2005;175:7311–24.

    Article  CAS  PubMed  Google Scholar 

  84. Gonzalez-Rey E, Chorny A, Fernandez-Martin A, Ganea D, Delgado M. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood. 2006;107:3632–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Abad C, Martinez C, Leceta J, Gomariz RP, Delgado M. Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy. J Immunol. 2001;167:3182–9.

    Article  CAS  PubMed  Google Scholar 

  86. Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M, et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn’s disease. Gastroenterology. 2003;124:961–71.

    Article  CAS  PubMed  Google Scholar 

  87. Delgado M, Martinez C, Pozo D, Calvo JR, Leceta J, Ganea D, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol. 1999;162:1200–5.

    CAS  PubMed  Google Scholar 

  88. Elekes K, Sandor K, Moricz A, Kereskai L, Kemeny A, Szoke E, et al. Pituitary adenylate cyclase-activating polypeptide plays an anti-inflammatory role in endotoxin-induced airway inflammation: in vivo study with gene-deleted mice. Peptides. 2011;32:1439–46.

    Article  CAS  PubMed  Google Scholar 

  89. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Martin J, Pozo D, Ganea D, et al. Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. Am J Pathol. 2006;168:1179–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Ji H, Zhang Y, Shen XD, Gao F, Huang CY, Abad C, et al. Neuropeptide PACAP in mouse liver ischemia and reperfusion injury: immunomodulation by the cAMP-PKA pathway. Hepatology. 2013;57:1225–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Dickinson T, Mitchell R, Robberecht P, Fleetwood-Walker SM. The role of VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an experimental peripheral mononeuropathy. Neuropharmacology. 1999;38:167–80.

    Article  CAS  PubMed  Google Scholar 

  92. Favrais G, Couvineau A, Laburthe M, Gressens P, Lelievre V. Involvement of VIP and PACAP in neonatal brain lesions generated by a combined excitotoxic/inflammatory challenge. Peptides. 2007;28:1727–37.

    Article  CAS  PubMed  Google Scholar 

  93. Reglodi D, Kiss P, Szabadfi K, Atlasz T, Gabriel R, Horvath G, et al. PACAP is an endogenous protective factor-insights from PACAP-deficient mice. J Mol Neurosci. 2012;48:482–92.

    Article  CAS  PubMed  Google Scholar 

  94. Gonzalez-Rey E, Delgado-Maroto V, Souza Moreira L, Delgado M. Neuropeptides as therapeutic approach to autoimmune diseases. Curr Pharm Des. 2010;16:3158–72.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Instituto de Parasitologia y Biomedicina Lopez-Neyra, CSIC, Avd. Conocimiento, PT Ciencias de la Salud, Granada, 18016, Spain

    Mario Delgado

Authors
  1. Mario Delgado
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mario Delgado .

Editor information

Editors and Affiliations

  1. Department of Anatomy MTA-PTE “Lendulet” PACAP Research Team, University of Pecs, Pecs, Hungary

    Dora Reglodi

  2. Department of Anatomy MTA-PTE “Lendulet” PACAP Research Team, University of Pecs, Pecs, Hungary

    Andrea Tamas

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Delgado, M. (2016). Immunobiology of the Pituitary Adenylate Cyclase-Activating Peptide. In: Reglodi, D., Tamas, A. (eds) Pituitary Adenylate Cyclase Activating Polypeptide — PACAP. Current Topics in Neurotoxicity, vol 11. Springer, Cham. https://doi.org/10.1007/978-3-319-35135-3_40

Download citation

Publish with us

Policies and ethics

Search

Navigation